Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TheraCardia Inc.

This article was originally published in Start Up

Executive Summary

Having focused largely on the drug component of drug-eluting stents, most companies developing the next wave of bioabsorbable stents are working with the same biopolymers. Theracardia, however, begins life with a portfolio of novel biopolymers that inherently have the potential to avoid inflammation in the body, are bioabsorbable and can be engineered to achieve specific biological effects. The company is validating its platform in a stent biocoating in preparation for developing its own improved bioabsorbable stent, one that, it hopes, will promote rapid endothelialization and reduce restenosis without incorporating a drug.

You may also be interested in...



Start-Up Previews (09/2007)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Eyes Still Have It," features profiles of Alacrity Biosciences, Eyeon Therapeutics, Mobius Therapeutics and OcuCure Therapeutics. Plus these Start-Ups Across Health Care: CyberHeart, GlycoVaxyn, TheraCardia and Vicus Therapeutics.

EuroPCR Highlights: CoStar Fizzles, Xience Sizzles

With a record attendance last month in Barcelona, the annual EuroPCR meeting gathered cardiologists from around the globe for live training sessions, challenging case reviews, trial updates, and data on rapidly evolving new technologies. Drug-eluting stents were high on the agenda with interesting data, but transcatheter heart valve replacement also generated significant interest with packed sessions and busy booths.

Arterial Remodeling Technologies

Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel